Page 1227 - Basic _ Clinical Pharmacology ( PDFDrive )

Index 1213

Gases, toxic, 1041t, 1043, 1044t “Gene-active” receptors, 27 nonadherence to, 1065
Gastric lavage, 1040 General anesthetics, 440. See Anesthetics, ophthalmic drugs
Gastrin (CCK-B) receptors, 1087–1088, general glaucoma, 1064
1088f Generalized seizures. See also Antiseizure macular degeneration, age-related,
Gastrinoma, 1094 drugs; Seizures 1065
Gastrin-releasing peptide (GRP), 92t definition of, 410 pharmacologic changes, 1059f,
Gastritis, stress-related drugs for, 426–430 1059–1061
H 2 -receptor antagonists for, 1091 divalproex sodium, 426f, 426–427 behavior and lifestyle, 1061
proton-pump inhibitors for, 1091 ethosuximide, 428–429, 433t, 437t pharmacodynamics, 1060–1061
Gastroesophageal reflux disease (GERD) phensuximide and methsuximide, pharmacokinetics, 1059t,
H 2 -receptor antagonists for, 1090 429f 1059–1060
metoclopramide for, 1097 valproic acid, 426f, 426–427, 436t principles for, 1065–1066
proton-pump inhibitors for, 1093 Generalized tonic-clonic seizures, 413–421. Germander, 1133t
Gastrointestinal cancers, chemotherapy for, See also Antiseizure drugs; Gestational diabetes mellitus, 752
972–973 Seizures Ghrelin, 747
Gastrointestinal disease drugs, 1087–1119, Generic prescribing, 1154–1155 Giardiasis, 933–934. See also Amebiasis
1115t–1116t. See also specific Generic product, 17 drugs
drugs Genetic factors, in drug metabolism, 65–69 Gigantism, 672
acid-peptic diseases, 1087–1095, 1115t pharmacogenetic testing in drug therapy, Gilbert’s syndrome, 69
antidiarrheals, 1100–1101, 1115t 69 Gilles de la Tourette syndrome, 505. See
antiemetics, 1103–1106, 1116t phase I enzyme polymorphisms in, Tourette syndrome
bile acid therapy for gallstones, 65–69, 66t–67t, 68f, 76t, 79t Ginkgo (Ginkgo biloba), 1136–1137
1113–1114, 1116t phase II enzyme polymorphisms in, 64f, Ginseng, 1137–1138
gastrointestinal motility stimulators, 69 G io protein-coupled receptors
1096–1098, 1115t Genetic variations, in drug metabolism, in addiction, 576, 577f
glucagon-like peptide 2 analog for short- 75–82 drugs activating, 581–583, 583f
bowel syndrome, 1113 glucose 6-phosphate dehydrogenase, cannabinoids, 577t, 581–582, 583f
inflammatory bowel disease, 1106–1112, 81–82, 82t gamma-hydroxybutyric acid, 577t,
1116t phase I enzymes in, 75–78, 76t–77t, 582, 583f
irritable bowel syndrome, 1101–1103, 79t–80t LSD, mescaline, and psilocybin, 577t,
1115t phase II enzymes in, 76t, 79t, 81 582–583
laxatives, 1098–1100, 1115t Genitourinary system, 148 Gland-derived extracts, 1133t
pancreatic enzyme supplements, Genome-wide association (GWA) studies, Glargine, 755, 769t. See also Insulin
1112–1113, 1116t 74 Glatiramer acetate (GA), 989
preparations available, 1117t Gentamicin Glaucoma drugs, 165b, 166t
variceal hemorrhage, 1114, 1116t description of, 827f, 830–831, 833t cholinomimetics, 118
Gastrointestinal motility topical dermatologic, 1071 Glia, 368, 368f
enteric nervous system in, 92, 1096– Geriatric pharmacology, 1058–1067 Glicentin, 750
1097, 1097f adverse drug reactions, 1065 Gliclazide, 759, 769t. See also Sulfonylureas
stimulators of, 1096–1098, 1115t androgens and anabolic steroids, 742 Glimepiride, 759, 769t. See also
cholinomimetic agents, 1097 anti-inflammatory drugs, 1064 Sulfonylureas
macrolides, 1098 antimicrobial therapy, 1064 Glipizide, 758–759, 769t. See also
mechanism of action of, 1096–1097, cardiovascular drugs Sulfonylureas
1097f antiarrhythmics, 1064 Glucagon, 165, 747, 749–751
metoclopramide and domperidone, antihypertensives, 1063 Glucagon-like peptide-1 (GLP-1) receptor
1097–1098 positive inotropes, 1064 agonists, 762, 769t
preparations available, 1117t central nervous system drugs, Glucagon-like peptide-1 (GLP-1), 762
Gastrointestinal tract 1061–1063 Glucagon-like peptide-2 analog, for
drug effects on, 1087 Alzheimer’s disease, 1062f, short-bowel syndrome, 1113
lead exposure effects on, 1022 1062–1063, 1063t Glucocorticoid antagonists, 715–717
methylxanthines effect on, 353 analgesics, 1061 Glucocorticoid receptor elements (GREs),
prostaglandins effect on, 327 antipsychotics and antidepressants, 705
thromboxanes effect on, 327 542t, 1061–1062 Glucocorticoid receptor (GR)
Gatifloxacin, 838 sedative-hypnotics, 1061 forms and interactions of, 705–707, 707f
Gemcitabine, 958t, 960, 973 drug taking errors from physical genes for, 705
Gemfibrozil, 634–635, 635f, 639t disability in, 1066 Glucocorticoid resistance, primary
Gemifloxacin, 838 expense of, 1065 generalized, corticosteroids for,
Gender, in drug metabolism, 69 fundamentals of, 1058–1059 710